A complex $26 billion global deal reaches a critical juncture on Friday: Drug companies must decide whether to walk away from an agreement to provide funds to nearly all 50 states and U.S. territories to abate costs caused by the opioid crisis. A key factor in that decision is how many of the thousands of cities and counties within each state chose to participate.

In the weeks leading up to the upcoming deadline, a handful of states, such as New Jersey and Connecticut, announced that 100% of their municipalities were on board with the deal, which involves a $5 billion agreement with manufacturer Johnson & Johnson’s Janssen Pharmaceuticals, and a $21 billion settlement with three drug distributors: AmerisourceBergen Drug Corp., McKesson Corp. and Cardinal Health Inc. Many, such as California and Florida, were close to that goal.